The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted the public to the recall of Mivacron and Nimbex injections over safety concerns.
NAFDAC disclosed this in a statement posted on Monday, noting that Aspen Pharmacare Asia Limited manufactured the affected products.
The agency said the recall followed safety concerns approved by the Hong Kong Department of Health.
According to NAFDAC, one batch of Mivacron Injection 0.2 per cent and five batches of Nimbex Injection 2mg/mL were affected.
“The recall was made as a precautionary measure due to potential quality issues identified by the manufacturer,” NAFDAC said.
Investigations by the agency revealed deficiencies in the manufacturer’s manual visual inspection process.
NAFDAC added that “not all glass particles in the ampoules were likely detected,” which prompted a voluntary market recall.
The injections, which contain mivacurium and cisatracurium, are prescription medicines used as adjuncts to general anaesthesia.
NAFDAC advised healthcare professionals and consumers to report suspected substandard medicines to its nearest office or through its e-reporting platforms.
NAN